265 related articles for article (PubMed ID: 22124940)
1. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.
Alexandraki KI; Kaltsas G
Endocrine; 2012 Feb; 41(1):40-52. PubMed ID: 22124940
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine tumor disease: an evolving landscape.
Frilling A; Akerström G; Falconi M; Pavel M; Ramos J; Kidd M; Modlin IM
Endocr Relat Cancer; 2012 Oct; 19(5):R163-85. PubMed ID: 22645227
[TBL] [Abstract][Full Text] [Related]
3. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
4. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
5. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
8. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.
Alexandraki KI; Karapanagioti A; Karoumpalis I; Boutzios G; Kaltsas GA
Biomed Res Int; 2017; 2017():9856140. PubMed ID: 29349087
[TBL] [Abstract][Full Text] [Related]
9. Treatment personalization in gastrointestinal neuroendocrine tumors.
Borga C; Businello G; Murgioni S; Bergamo F; Martini C; De Carlo E; Trevellin E; Vettor R; Fassan M
Curr Treat Options Oncol; 2021 Feb; 22(4):29. PubMed ID: 33641005
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
[TBL] [Abstract][Full Text] [Related]
11. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
12. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Eriksson B
Curr Opin Oncol; 2010 Jul; 22(4):381-6. PubMed ID: 20473165
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
14. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
Halperin DM; Kulke MH; Yao JC
Annu Rev Med; 2015; 66():1-16. PubMed ID: 25341008
[TBL] [Abstract][Full Text] [Related]
15. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.
Schimmack S; Svejda B; Lawrence B; Kidd M; Modlin IM
Langenbecks Arch Surg; 2011 Mar; 396(3):273-98. PubMed ID: 21274559
[TBL] [Abstract][Full Text] [Related]
16. Current Concepts in the Management of GEP-NETs: Introduction.
Iyer R
Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 6):3-4. PubMed ID: 27167990
[No Abstract] [Full Text] [Related]
17. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014.
Garcia-Carbonero R; JImenez-Fonseca P; Teulé A; Barriuso J; Sevilla I;
Clin Transl Oncol; 2014 Dec; 16(12):1025-34. PubMed ID: 25183048
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
Lindholm DP; Oberg K
Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
[TBL] [Abstract][Full Text] [Related]
19. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
